What Is Valued Most by Patients With Type 2 Diabetes Mellitus When Selecting Second-Line Antihyperglycemic Medications in China

Abstract

Objective: To estimate patient preferences for second-line antihyperglycemic medications in China.Methods: A face to face survey with the best-worst scaling (BWS) choices was administered in patients with diagnosed type 2 diabetes mellitus (T2DM). Study participants were asked to indicate which attribute they valued most and which attribute they valued least in 11 choice sets, each of which consisted of five alternatives out of 11 antihyperglycemic medication-specific attributes (treatment efficacy, weight change, hypoglycemic events, gastrointestinal side effects, cardiovascular health, urinary tract infection and genital infection side effects, edema, mode of administration, bone fracture, dosing frequency and out-of-pocket cost). A counting approach, a conditional logit model, and K-means clustering were used to estimate the relative importance of items and preference heterogeneity.Results: A total of 362 participants were included with a mean age of 63.6 (standard deviation: 11.8) years. There were 56.4% of participants were women, and 56.3% being diagnosed with diabetes for at least 5 years. Efficacy, cardiovascular health and hypoglycemic events were valued most, while dosing frequency, mode of administration and bone fracture were valued least. The K-means clustering further showed preference heterogeneity in out-of-pocket cost across the participants.Conclusion: Our study suggests that treatment efficacy, cardiovascular health and hypoglycemic events are valued most by Chinese patients with T2DM when selecting second-line antihyperglycemic medications. The study improves the understanding of patients’ preferences for second-line antihyperglycemic medications in China.

Assessing patient information needs for new antidiabetic medications to inform shared decision‐making: A best–worst scaling experiment in China

“…For example, a survey showed that cardiovascular health and clinical benefits were most valued among diabetic patients when selecting second‐line antidiabetic medications. 40 Treatment outcomes, including the control of HbA 1c , glycemic stability, and cardiovascular events, were highly valued by diabetic patients in another survey. 41 …”

“…For example, a survey showed that cardiovascular health and clinical benefits were most valued among diabetic patients when selecting second-line antidiabetic medications. 40 Treatment outcomes, including the control of HbA 1c , glycemic stability, and cardiovascular events, were highly valued by diabetic patients in another survey. 41 A new finding in our study is that to facilitate the SDM, patients had the greatest interest in whether new antidiabetic medications could reduce the incidence of macrovascular complications.…”

“…Patient information needs on the comparative effectiveness of new medications were consistent with prior studies on patient preferences for antidiabetic therapeutics. For example, a survey showed that cardiovascular health and clinical benefits were most valued among diabetic patients when selecting second‐line antidiabetic medications 40 . Treatment outcomes, including the control of HbA 1c , glycemic stability, and cardiovascular events, were highly valued by diabetic patients in another survey 41 …”

Patient preferences for anti-hyperglycaemic medication for type 2 diabetes mellitus in China: findings from a national survey

“…The BWS results provided a clear view of the priority of the 11 attributes. Details of the BWS results can be found in the study by Liu et al 19 These attributes were further refined through focus-group discussions with six endocrinologists in Shanghai, China.…”